Want to see BCAX full AI Analyst Report?
BCAX Stock Chart & Stats
$27.02
$0.79(2.92%)
At close: 4:00 PM EDT
$27.02
$0.79(2.92%)
Day’s Range― - ―
52-Week Range$9.57 - $30.99
Previous Close$27.81
Volume499.45K
Average Volume (3M)829.98K
Market Cap
$1.77B
Enterprise Value$669.35
Total Cash (Recent Filing)$539.75M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 18, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.78
Shares Outstanding65,703,865
10 Day Avg. Volume408,617
30 Day Avg. Volume829,976
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.29
Price to Sales (P/S)0.00
P/FCF Ratio-8.59
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$32.11Price Target Upside18.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet & RunwayA large cash position provides a multi-year runway to complete pivotal FORTIFI‑HN01, conduct the alternative dosing study, and fund prelaunch builds without immediate financing. This materially reduces near-term dilution risk and enables execution of long‑lead clinical and commercial milestones through mid‑2029.
Compelling Clinical Efficacy SignalsDurable responses and multi-year survival in the 1,500 mg cohort indicate potential best‑in‑class activity and a biologic mechanism (TGF‑β inhibition) that drives depth and durability. These durable efficacy signals strengthen the regulatory case for accelerated pathways and underpin sustainable commercial differentiation if confirmed in Phase III.
Commercial & Leadership Build‑outDeliberate hires and promotions signal a credible transition toward commercialization capability, including market access and launch planning. Building experienced commercial leadership and governance improves preparedness for launch, pricing, and provider adoption—structural advantages that persist beyond near‑term data releases.
Bears Say
Pre‑revenue With Material LossesBeing pre‑revenue with rapidly widening losses means the company is reliant on capital markets or milestones to fund operations until commercialization. Persistent negative returns and expanding operating deficits increase the probability of future equity raises, which can dilute shareholders and pressure strategic flexibility over the medium term.
Rising Operating & Commercial ExpensesAs Bicara shifts toward commercial readiness, SG&A, manufacturing and personnel costs are ramping. Structural increases in operating spend will raise steady cash burn and may shorten effective runway if revenue or non‑dilutive funding does not materialize, elevating execution and funding risk during the commercialization transition.
Regulatory & Data‑Maturity UncertaintyA randomized dosing study without a formal non‑inferiority design and immature cohort follow‑up create structural regulatory and interpretive risk. Unclear design margins and limited maturity may complicate label claims, commercial dosing adoption, and payer acceptance, potentially delaying market access or necessitating additional studies.
Bicara Therapeutics Inc. News
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $9.57 and its highest was $30.99 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $1.77B.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
Bicara Therapeutics Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 19 days.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on May 11, 2026. The company reported -$0.93 earnings per share for the quarter, missing the consensus estimate of -$0.649 by -$0.281.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate is -0.82.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 65,703,865 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$0.93 in its last earnings report, missing expectations of -$0.649. Following the earnings report the stock price went up 1.506%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicara Therapeutics Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.11 (18.84% Upside)
$32.11 (18.84% Upside)
Blogger Sentiment
Bullish
BCAX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 474.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.80%
Trailing 12-Months
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
BCAX Company Deck
BCAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive clinical momentum for ficera (deep, durable responses, peer-reviewed publication, planned pivotal interim in mid-2027 and upcoming 3‑year ASCO data), meaningful commercial and organizational build-out, and a bolstered balance sheet providing runway into H1 2029. Offsetting risks include rising operating expenses, limited size/maturity of some cohorts, regulatory/design considerations for the alternative dosing study, and competitive/expansion challenges in tough indications like CRC. On balance, the highlights — notably compelling clinical efficacy signals and secured funding — substantially outweigh the lowlights, but key open milestones (ASCO updates, interim analysis, alternative dosing readout) remain important near‑term catalysts and risks.View all BCAX earnings summariesBCAX Stock 12 Month Forecast
Average Price Target
$32.11
▲(18.84% Upside)
Technical Analysis
Sarepta Therapeutics
―
Wave Life Sciences
―
Intellia Therapeutics
―
Stoke Therapeutics
―
Taysha Gene Therapies
―
Ownership Overview
21.71% Insiders
16.05% Mutual Funds
5.82% Other Institutional Investors
45.87% Public Companies and
Individual Investors